Abbott
ABT · NYSE · United States
Share price · ABT
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when ABT's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 6 Nov 2026-3.2%
Nothing announced by ABT that day or the session before.
- 2 Nov 2026+3.7%
- 16 Jul 2026+10.7%
- 1 Jun 2026+2.5%
Nothing announced by ABT that day or the session before.
- 18 May 2026+4.1%
Nothing announced by ABT that day or the session before.
- 16 Apr 2026-6.0%
- 22 Jan 2026-10.0%
- 5 Jan 2026+1.8%
- 19 Nov 2025-3.0%
Nothing announced by ABT that day or the session before.
Share of unusual movement by asset
For each asset, the share of ABT's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | PD-1Monoclonal antibody | Non-Small Cell Lung CancerSmall Cell Lung CancerGastric Cancer |
Upcoming events
(5 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (4)
May 2027 (1)
What to watch
June 2027 (1)
What to watch
July 2027 (1)
What to watch
December 2027 (1)
What to watch
2031 (1)
January 2031 (1)
What to watch
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $13.0B | $920M | $4.1B+ $246M short-term inv. | —$1.7B operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $12.6B | $892M | $5.1B+ $499M short-term inv. | —$2.5B operating cash flow | report ↗ |
| 2026-Q1 | $11.2B | $767M | $6.8B+ $492M short-term inv. | —$1.3B operating cash flow | report ↗ |
| 2025-Q3 | $11.4B | $766M | $7.5B+ $222M short-term inv. | —$2.8B operating cash flow | report ↗ |
| 2025-Q2 | $11.1B | $725M | $7.0B+ $331M short-term inv. | —$2.0B operating cash flow | report ↗ |
| 2025-Q1 | $10.4B | $716M | $6.5B+ $312M short-term inv. | —$1.4B operating cash flow | report ↗ |
| 2024-Q3 | $10.6B | $713M | $7.6B+ $230M short-term inv. | —$2.7B operating cash flow | report ↗ |
| 2024-Q2 | $10.4B | $698M | $7.0B+ $232M short-term inv. | —$2.0B operating cash flow | report ↗ |
| 2024-Q1 | $10.0B | $684M | $6.3B+ $367M short-term inv. | —$1.0B operating cash flow | report ↗ |
| 2023-Q3 | $10.1B | $672M | $6.7B+ $338M short-term inv. | —$1.9B operating cash flow | report ↗ |
| 2023-Q2 | $10.0B | $715M | $7.8B+ $320M short-term inv. | —$1.2B operating cash flow | report ↗ |
| 2023-Q1 | $9.7B | $654M | $9.2B+ $371M short-term inv. | —$1.1B operating cash flow | report ↗ |
| 2022-Q3 | $10.4B | $782M | $9.6B+ $313M short-term inv. | —$2.8B operating cash flow | report ↗ |
| 2022-Q2 | $11.3B | $684M | $8.9B+ $353M short-term inv. | —$2.4B operating cash flow | report ↗ |
| 2022-Q1 | $11.9B | $697M | $7.7B+ $483M short-term inv. | —$2.1B operating cash flow | report ↗ |
| 2021-Q3 | $10.9B | $672M | $9.3B+ $390M short-term inv. | —$2.7B operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $44.3B | $2.9B | $8.5B+ $417M short-term inv. | —$9.6B operating cash flow | report ↗ |
Abbott reported revenue of $44,328M, up 5.7% YoY, with R&D spend of $2,942M, up 3.4% YoY. Cash and equivalents stood at $8,522M, and the company reported net income of $6,524M.
The filing provides segment-level detail across established pharmaceutical products, nutritional products, diagnostics, and medical devices, alongside a 2025 restructuring plan to streamline operations. It also discloses a November 19, 2025 transaction involving Exact Sciences Corporation supported by a senior unsecured bridge term loan facility. No forward-looking guidance is stated in the provided material.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $42.0B | $2.8B | $7.6B+ $351M short-term inv. | —$8.6B operating cash flow | report ↗ |
| 2023-FY | $40.1B | $2.7B | $6.9B+ $383M short-term inv. | —$7.3B operating cash flow | report ↗ |
| 2022-FY | $43.7B | $2.9B | $9.9B+ $288M short-term inv. | —$9.6B operating cash flow | report ↗ |
| 2021-FY | $43.1B | $2.7B | $9.8B+ $450M short-term inv. | —$10.5B operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 6 purchases ($4.4M), 12 sales ($47.9M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-05 | Moreland Mary K · EXECUTIVE VICE PRESIDENT | Open-market sale | 3,500 | $116.00 | $406K | Form 4 |
| 2026-09-30 | Roman Michael F · director | Award / grant (derivative) | 381 | $98.83 | $38K | Form 4 |
| 2026-09-30 | Ahuja Nita · director | Award / grant (derivative) | 318 | $98.83 | $31K | Form 4 |
| 2026-09-30 | Conroy Kevin T · director | Award / grant (derivative) | 318 | $98.83 | $31K | Form 4 |
| 2026-09-30 | Gonzalez Patricia Paola · director | Award / grant (derivative) | 333 | $98.83 | $33K | Form 4 |
| 2026-09-30 | Stratton John G · director | Award / grant (derivative) | 397 | $98.83 | $39K | Form 4 |
| 2026-09-23 | Conroy Kevin T · director | Tax withholding | 52,507 | $103.99 | $5.5M | Form 4 |
| 2026-09-02 | MCCOY JOHN A. JR. · VICE PRESIDENT AND CONTROLLER | Open-market sale | 27 | $109.54 | $3K | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 3,062 reporting institutions held 1374.3M shares ($136.2B, 79.4% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | BlackRock, Inc. | 145,687,458 | $15.0B |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 112,949,933 | $11.6B |
| 3 | STATE STREET CORP | 79,575,468 | $8.2B |
| 4 | Capital Research Global Investors | 49,775,362 | $5.1B |
| 5 | VANGUARD PORTFOLIO MANAGEMENT LLC | 47,944,891 | $4.9B |
| 6 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 45,500,055 | $4.7B |
| 7 | GEODE CAPITAL MANAGEMENT, LLC | 39,148,795 | $4.0B |
| 8 | Capital International Investors | 37,498,227 | $3.8B |
| 9 | MORGAN STANLEY | 30,101,596 | $3.1B |
| 10 | WELLINGTON MANAGEMENT GROUP LLP | 27,070,518 | $2.8B |
| 11 | JPMORGAN CHASE & CO | 26,767,099 | $2.7B |
| 12 | FRANKLIN RESOURCES INC | 20,022,905 | $2.1B |
| 13 | NORTHERN TRUST CORP | 19,394,974 | $2.0B |
| 14 | BANK OF AMERICA CORP /DE/ | 19,279,608 | $2.0B |
| 15 | WELLS FARGO & COMPANY/MN | 15,909,341 | $1.6B |